Gene Mack - 08 Apr 2024 Form 4 Insider Report for Gain Therapeutics, Inc. (GANX)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	GANX	Employee Stock Option (right to buy)	Award	$0	+200,000		$0	200,000	08 Apr 2024	Common Stock	200,000	$3.56	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	The shares underlying the option shall vest 25% on April 8, 2025 and the remainder shall vest in 36 equal monthly installments thereafter, subject to Reporting Person's continuous service through each such vesting date.